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Abstract
Leveraging preclinical animal data for a phase I first-in-man trial is appealing yet challenging. A
prior based on animal data may place large probability mass on values of the dose-toxicity model
parameter(s), which appear infeasible in light of data accrued from the ongoing phase I clinical trial.
In this paper, we seek to use animal data to improve decision making in a model-based dose-escalation
procedure for phase I oncology trials. Specifically, animal data are incorporated via a robust mixture
prior for the parameters of the dose-toxicity relationship. This prior changes dynamically as the trial
progresses. After completion of treatment for each cohort, the weight allocated to the informative
component, obtained based on animal data alone, is updated using a decision-theoretic approach to
assess the commensurability of the animal data with the human toxicity data observed thus far. In
particular, we measure commensurability as a function of the utility of optimal prior predictions for
the human responses (toxicity or no toxicity) on each administered dose. The proposed methodology is
illustrated through several examples and an extensive simulation study. Results show that our proposal
can address difficulties in coping with prior-data conflict commencing in sequential trials with a small
sample size.
1 Introduction
Phase I oncology trials are performed primarily to characterise the toxicity profile of an anticancer ther-
apy in human subjects. Regulatory authorities require that first-in-man trials be preceded by non-clinical
safety studies in at least two animal species, including the most sensitive and relevant species [1, 2]. It is
therefore reasonable to assume that some animal data will be available at the time of designing a phase
I clinical trial. Despite this availability, trialists may be uncertain about how and whether to leverage
animal data. On the one hand, there is considerable motivation to design and conduct more efficient
phase I clinical trials, basing interim dose-escalation decisions on relevant information internal and ex-
ternal to the trial [3, 4]. On the other hand, leveraging animal data could risk patient safety [5, 6, 7],
if it emerges that parameters of the human dose-toxicity relationship, predicted from animal data, are
non-exchangeable with the parameters of the true (but unknown) human relationship. In this paper, we
propose a quantitative approach for leveraging preclinical animal data for the design and interpretation
of a phase I first-in-man trial.
There exists Bayesian and frequentist approaches for incorporating historical data into the analysis of
a new clinical trial [8]. This paper will focus on Bayesian approaches for leveraging historical, or more
generally, complementary (co-)data [4], comprising all relevant historical and concurrent data into a new
study. Proposals include power priors [9, 10, 11], commensurate priors [12, 13] and robust meta-analytic
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predictive priors [14, 15]. Power priors are so-called because this approach raises the likelihood of the
co-data to a power weight between 0 and 1. This exponent can be treated as a constant and could be
fixed in advance on the basis of our prior scientific understanding of the similarity of parameters un-
derpinning the distributions of the co-data and the new data. Alternatively, Gravestock and Held [16]
adopt an adaptive versions of the power prior, which estimate the power using an empirical Bayes ap-
proach, and fix the power equal to the estimate maximising the marginal likelihood of the historical and
new data. The normalised power prioradopt an empirical Bayes approach, and fix the power equal to
the estimate maximising the marginal likelihood of the historical and new data. The normalised power
prior [10] treats the exponent as a random variable, with a prior distribution which is updated once the
new data are observed. A prior-data conflict will result in a posterior placing probability mass on powers
close to 0, thus down-weighting the contribution of the co-data to the posterior of the parameter of interest.
Other examples of Bayesian dynamic priors, where the degree of down-weighting reacts to the similar-
ity of the observed and historical data include commensurate priors and meta-analytic predictive priors.
Commensurate priors [12] stipulate a conditional prior for the parameter underpinning the distribution
of the new trial data, which is centred at the historical data parameter and has precision parameter for
capturing the commensurability of the co-data and new trial data. Hobbs et al. [13] present empirical and
fully Bayesian modifications of the commensurate prior to general and generalised linear models. Meta-
analytic approaches leveraging co-data assume that parameters underpinning the historical trials and the
new trial are exchangeable, that is, are conditionally independent draws from a distribution, for example,
a normal distribution with unknown mean µ and variance τ2. Here τ captures the degree of heterogeneity
between parameters underpinning different trials, with larger values leading to greater attenuation of the
co-data. To encourage faster discounting of the historical data when there is a prior-data conflict, Schmidli
et al. [15] develop a robust heavy-tailed prior [17], which is a two-component mixture distribution with
one component the meta-analytic predictive prior and the other a weakly-informative (proper) distribu-
tion. Mutsvari et al. [18] discuss how to stipulate this weakly informative component for a robust inference.
Application of these methods has mainly been found in phase II clinical trials for borrowing of in-
formation from a historical control to the concurrent control. In general, incorporating historical control
data would result in benefits such as increasing power and potentially reducing the sample size when a
discrepancy between historical and concurrent control is small [19, 20]. However, very little has been
written on leveraging historical data, particularly the preclinical animal data, into phase I dose-escalation
studies, where metrics for assessing the benefits of borrowing towards the trial operating characteristics
are very different from those appropriate in the context of phase II clinical trials for efficacy. Zheng et al.
[21] propose a robust Bayesian hierarchical random-effects model to incorporate data from multiple studies
performed in one or more animal species into the analysis of a phase I oncology trial. The dose-toxicity
relationship learned from animal data is projected onto an equivalent human dosing scale, using a trans-
lation parameter formulated from allometric scaling. A log-normal prior, appropriate for each species, is
specified for the translation parameter to describe uncertainty about the magnitude of differences in toxi-
city between animals and humans. This then leads to a feasible assumption that the standardised animal
parameters are exchangeable with the human parameters of the logistic dose-toxicity model. Possibility
of non-exchangeability of parameters is also considered. The robust Bayesian hierarchical model is best
fitted with animal data collected from several studies that have evaluated a number of doses.
In this paper, we represent preclinical animal data in a bivariate normal prior for the parameters of the
human dose-toxicity relationship, assuming this can be adequately described by a two-parameter logistic
regression model [22, 23]. We analyse the accumulating human data on dose-limiting toxicities (DLTs)
using a mixture prior that comprises (i) an informative component based on the animal data and (ii) a
weakly informative prior. We use empirical mixture weights, which are updated at each interim analysis
of the adaptive Bayesian dose-escalation trial by comparing the human data observed thus far with what
2
we would expect based on the animal data. Decision-making in our context about incorporating animal
data or not seems to be an ideal setup to apply the Bayesian decision theory, which has been widely
considered in early phase clinical trials to quantify the trade-off between various decisions using proba-
bilities and costs [24]. Stallard and Thall [25] develop a decision-theoretic approach to the selection of
candidate treatments prior to a phase II oncology trial. Hee and Stallard [26] discuss a kind of sequential
design, wherein a series of phase II trials and a phase III trial are conducted in a row, relating the decision
of continuing recruitment or termination with the consequences in long-term. Articles using Bayesian
decision theory to make phase I trials more ethical include Whitehead and Brunier[27], Whitehead and
Williamson [22], and Whitehead et al. [28].
In our problem, incorporating different types of animal data, which may over- or under-predict the
toxicity in humans, will result in very different dose recommendations for patients who will enter the trial
at later stages. We thus propose using Bayesian decision theory to measure the commensurability of the
animal and human data, so as to update the empirical mixture weight along as the trial progresses. Adapt-
ing the idea of Fouskakis and Draper [29], we assess the commensurability using the discrepancy between
predicted human toxicity, based on the animal data, with observed human responses. More specifically,
before patients of a new cohort is treated, animal data are used to derive optimal prior predictions for
the human DLT outcomes at the dose recommended. Predictions are optimal in the sense that they have
maximum expected utility, where utilities are defined as dimensionless quantities between 0 and 1, with
higher utilities assigned to correct predictions and vice versa. Once the human DLT outcomes from the
latest cohort are observed, commensurability of the human and animal data is measured by the attained
utility (which we will refer to as predictive utility) of the predictions, averaging across relevant doses used
thus far in the trial. This measure of commensurability determines the weight assigned to the informative
component of the mixture prior (based on the animal data) that is used to analyse the data accrued thus
far and deduce the dose recommendation for the next patient cohort.
The remainder of the paper is structured as follows. Starting with a motivating example in Section
2, we explain in Section 3 how preclinical data from a single animal species on two or more doses can be
represented in a bivariate normal prior for the dose-toxicity parameters of the human trial. In Section
4, we propose a Bayesian decision-theoretic approach to adaptively leverage animal data according to a
formal assessment of commensurability. We then retrospectively design and analyse the example trial
applying the proposed methodology in section 5, and describe a simulation study performed to evaluate
the operating characteristics of a Bayesian phase I dose-escalation study in Section 6. We close with a
discussion of our findings and future research interest in Section 7.
2 Motivating example
Sessa et al. [30] report a phase I first-in-man trial intended to estimate the maximum tolerated dose
(MTD) of the anticancer therapy AUY922. The trial enrolled 101 patients who were treated sequentially
in cohorts of size three or more. Patients were monitored to record whether or not they experienced
a dose-limiting toxicity (DLT). Nine doses were evaluated during the study, summarised by the dosing
set D = {2, 4, 8, 16, 22, 28, 40, 54, 70} mg/m2. Dose-escalation decisions were guided by a two-parameter
Bayesian logistic regression model (BLRM) for the relationship between dose and DLT risk [23]. The model
was implemented placing weakly informative priors on the model parameters consistent with median DLT
probabilities of around 0.1% and 33% at doses 2 and 28 mg/m2, respectively; these settings were informed
by data from toxicology studies performed in dogs [30], although the animal data were not formally
incorporated into the analysis of the phase I trial. Let pi denote the DLT risk on the ith largest dose in
D, di, and let x(h−1)H be a vector of observed outcomes from the first (h − 1) cohorts of patients. Then
the BLRM procedure recommends that the cohort h receives dose d
(h)
sel , defined as the highest dose in D
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with an acceptable risk of excessive toxicity:
d
(h)
sel = max{di ∈ D : P(pi ≥ 0.33|x(h−1)H ) ≤ 0.25}. (1)
Sessa et al. [30] implemented the BLRM-guided escalation procedure with the additional constraint that
d
(h)
sel should not exceed more than a two-fold increase in the current dose.
The AUY922 phase I clinical trial prompts the following questions:
(i) How can we formally incorporate preclinical data into prior distributions for the dose-toxicity model
parameters?
(ii) How can we dynamically update these priors in response to the observed prior-data conflicts, par-
ticularly when few data are available, as is often the case in a phase I trial?
These questions will motivate the methodology developed in Sections 3 and 4. In what follows, we will
define the MTD as the dose associated with a target DLT risk of Γ.
3 Representing animal data in a prior for dose-toxicity parameters
In this section, we outline our approach for leveraging animal data in a phase I dose-escalation study. Let
D = {d1, . . . , dI ; dt1 < dt2 for 1 ≤ t1 < t2 ≤ I} contain all doses available for evaluation. Furthermore,
let ni denote the number of patients treated with dose di, of whom ri experience a DLT. Several authors
[21, 22, 23] have used a two-parameter BLRM to inform dose escalation decisions in a phase I trial. We
follow these authors to assume that DLT risk increases monotonically with dose and that this relationship
can be described as:
ri|pi, ni ∼ Binomial(pi, ni), for i = 1, . . . , I,
logit(pi) = θ1 + exp(θ2) log(di/dRef),
(2)
where dRef is a pre-defined reference dose drawn from D and θ1 is the log-odds of toxicity on dRef. In
what follows, we are interested in estimating the dose-toxicity parameter vector θ = (θ1, θ2).
Suppose that when planning the first-in-man trial, data are available from one preclinical study per-
formed in a single animal species thought to be relevant for predicting DLT risks in humans. At a
minimum, data must be available on at least two doses and at least one toxicity must have been observed
on the highest dose. For ease of explanation, we now proceed assuming we have preclinical data on two
doses. Indexing animal doses by j = 0,−1, if tAj animals out of a total of (tAj + νAj) administered dose
dAj experienced a toxicity, we can represent the animal data by xA = {(dAj , tAj , vAj); j = −1, 0}. We
follow Zheng et al. [21] and use allometric scaling on the basis of body surface area [1, 31] to translate
the animal dose-toxicity curve onto an equivalent human dosing scale, assuming differences in DLT risk
between an animal species and humans, given the same dose, can be largely explained by differences in
size. In this way, we can identify doses d−1 and d0 such that, for j = 0,−1, the risk of a DLT in humans
given dose dj is anticipated to be similar to the risk of a DLT in animals given dose dAj . Doses d−1 and d0
are not necessarily contained in D. For j = −1, 0, we stipulate an independent prior pj ∼ Beta(tAj , vAj)
for the DLT risk in humans given dose dj , which has effective sample size (ESS) equal to (tAj + vAj) [32].
Thus, the translated preclinical data on animal dose dAj are taken to represent observations on (tAj+vAj)
patients on dose dj .
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Using these independent Beta priors for p−1 and p0, and assuming the dose-toxicity relationship follows
Model (2), we can apply a Jacobian transformation to obtain the joint prior probability density function
(pdf) of θ2 and pi, for 1 ≤ i ≤ I, as:
gi(pi, θ2 | xA) = 1
pi(1− pi) exp(θ2)
∣∣∣∣log(d−1d0
)∣∣∣∣× 0∏
j=−1
[1 + exp(−zji)]−tAj [1 + exp(zji)]−vAj
B(tAj , vAj)
, (3)
where zji = logit(pi) + exp(θ2) log(dj/dRef), for j = −1, 0; and B(a, b) is the Beta function evaluated at
(a, b). A detailed derivation of gi(pi, θ2 | xA) is provided in Appendix A. The marginal prior pdf of pi is
given by
fi(pi | xA) =
∫ +∞
−∞
gi(pi, θ2 | xA)dθ2 for 0 < pi < 1, (4)
and the prior cumulative distribution function (cdf) for pi evaluated at pi = p is
Fi(p | xA) =
∫ p
0
fi(pi | xA)dpi =
∫ p
0
∫ ∞
−∞
gi(pi, θ2 | xA)dθ2dpi for 0 < p < 1. (5)
We outline below how we can represent the preclinical information on toxicity probabilities, p1, . . . , pI ,
by a bivariate normal prior for θ, the vector of dose-toxicity parameters. The general idea of finding an
approximate prior for θ by matching percentiles of the marginal priors for p1, . . . , pI is due to Neuen-
schwander et al. [23].
(i) For each i = 1, . . . , I, summarise the prior for pi defined by cdf (5) by K percentiles. We recommend
using three (or more) percentiles. In our illustrative examples, we find the median, together with the
2.5th and 97.5th percentiles. The (100tik)th percentile, denoted by q(tik), is found as the solution
to:
P(pi ≤ q(tik) | xA) =
∫ q(tik)
0
∫ ∞
−∞
gi(pi, θ2 | xA)dθ2dpi = tik.
For ease of presentation, we will write qik = q(tik).
(ii) We stipulate θ ∼ BVN(µ, Σ). We then use a modified quasi-Newton algorithm [33], with constraints
set to the correlation of θ1 and θ2, to search over configurations of µ and Σ to find the one minimising
the total absolute distance between percentiles of the fitted marginal priors for the pi, denoted
by q′11, . . . , q′1K , . . . , q
′
I1, . . . , q
′
IK , and the orginal percentiles calculated in step (i). This distance
measure is formally defined as:
δ =
I∑
i=1
K∑
k=1
|qik − q′ik|.
Hereafter, we denote the pdf of the bivariate normal prior for θ as pi0(θ|xA). The above approach for
deriving pi0(θ|xA) assumed we had animal data on two doses. If instead we had data on more than two
doses, we would use these to first derive independent beta priors for the DLT risk on each corresponding
human dose; calculate the (100ti1)th, . . . , (100tiK)th percentiles of each beta prior; and then follow steps
(i) and (ii) to find a bivariate normal approximation to the prior for θ.
It is possible that human data from the phase I clinical trial may conflict with what was expected
based on pi0(θ|xA). Figure 1 illustrates four ways in which preclinical data could conflict with the true
(unknown) dose-toxicity relationship in humans. Preclinical data can (A) consistently over-predict or (B)
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Figure 1: Potential conflicts between priors based on preclinical data and the (unknown) human dose-toxicity relationship. For each
dose, the blue point and line represent the prior median and 95% credible interval for the DLT risk in humans based on preclinical
information. The orange point represents the actual risk in humans.
consistently under-predict the human DLT risk, or a mixture of (A) and (B), over the therapeutic interval
where doses have a DLT risk close to the target of Γ = 0.25. We want to leverage the preclinical data
to support inferences about θ when the animal data are highly predictive of human data and quickly
discount them otherwise. Another consideration is that the consequence of the prior-data conflict shown
in Figure 1A may be quite different to that of the conflict shown in Figure 1B. This is because leveraging
preclinical data to inform dose recommendations when they under-predict the human DLT risk may lead
to overdosing patients and placing them at excessive risk.
To facilitate robust borrowing of information across species, we implement Bayesian dose-escalation
procedures with a robust mixture prior for θ, which is a weighted average of an informative component,
taken as pi0(θ|xA), and a weakly informative component, denoted by m0(θ). Robust mixture priors have
been proposed to leverage historical controls in a new clinical trial [15] and to extrapolate adult data to
paediatrics [34, 35]. Denoting the prior weight attributed to the informative component by w, a mixture
prior can be written as
µ0(θ | xA) = w · pi0(θ | xA) + (1− w) ·m0(θ). (6)
Rather than defining m0(θ) as a non-informative prior, we specify it so as to place probability mass on a
wide range of plausible parameter values. We define m0(θ) as the pdf of a bivariate normal distribution
with correlation coefficient 0, setting dRef as the dose in D most likely to be associated with target
DLT risk Γ. We then stipulate θ1 ∼ N(m01, σ201), calibrating m01 and σ01 to ensure the median for the
DLT risk on dose dRef is Γ and the 95% credible interval is wide, say 0.01 to 0.95. A normal prior for
θ2 ∼ N(m02, σ202) is calibrated to accommodate very flat to steep dose-toxicity curves in humans. The
illustrative examples and simulation study described in Sections 5 and 6 are performed defining m0(θ) so
as to place independent priors on θ1 and θ2 with θ1 ∼ N
(
logit(Γ), 22
)
and θ2 ∼ N(0, 12).
4 Leveraging animal data using a mixture prior with dynamic weights
In this section, we propose analysing data from a phase I trial using a two-component mixture prior with
dynamically chosen weights. Specifically, after completion of cohort h, we use Bayes Theorem to update
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the prior distribution
µ
(h)
0 (θ | xA) = w(h) · pi0(θ | xA) + (1− w(h)) ·m0(θ), (7)
with the trial data from cohorts 1, . . . , h to derive the posterior distribution for θ. The posterior formed
by updating pi0(θ|xA) with human data will also be a two-component mixture [36], where the posterior
weights will reflect the relative likelihood of the human data under each component of the prior. Note
that pi0(θ|xA) and m0(θ) in (7) are as defined in Section 3, and do not depend on h. The cohort-specific
prior mixture weight w(h) ∈ [0, 1] measures the similarity of the animal data and human data from cohorts
1, . . . , (h− 1). Weight w(1) will best be based on expert prior opinion on the degree of similarity between
the prior predictive distribution for the human dose-toxicity relationship formed from preclinical data,
and the unknown human relationship. Rather than using a prior with the same prior mixture weight, say,
w(1), at each interim analysis, we revise this weight as the trial progresses. We update the prior weight
to encourage faster discounting of the preclinical data in the event of a prior-data conflict, to help ensure
patient safety. In the following, we develop a Bayesian decision-theoretic framework for how to select w(h)
during an ongoing phase I dose-escalation trial.
4.1 Assessment of commensurability using a Bayesian decision-theoretic approach
Let Yi represent the binary DLT outcome of a new patient assigned dose di ∈ D, such that Yi = 1 when
a patient experiences a DLT, and Yi = 0 otherwise. Furthermore, let y˜i denote the realisation of Yi. The
prior predictive probability mass function of Yi given the animal data is written as:
Pr(Yi = y˜i|xA) =
∫ 1
0
py˜ii · (1− pi)1−y˜ifi(pi|xA)dpi for y˜i ∈ {0, 1}, (8)
where fi(pi|xA) is the pdf of the marginal prior for pi, defined in (4), for i = 1, . . . , I. Before a patient
is treated, we can use the prior predictive distribution (8) to derive a prediction, ηi, for Yi [37]. At any
point before or during the phase I trial, the same outcome is predicted for all patients administered a
particular dose. After the patient’s outcome is observed, we can compare Yi with ηi and compute the
utility of the prediction. Let U(y˜ = `, η = s) denote the utility of prediction η = s for observation y˜ = `,
which can take values u`s, for `, s ∈ {0, 1}. Utilities are dimensionless quantities, independent of dose,
which lie between 0 and 1. Table 1 lists all possible configurations of the predicted and observed DLT
outcomes, and corresponding utilities. We consider schemes setting u00 = u11 = 1, thus assigning correct
predictions a utility of 1, and setting u10 = 0, that is, assigning an incorrect prediction of no DLT zero
utility. We explore setting u01 = b, with 0 < b < 1, since incorrectly predicting a no DLT outcome as a
DLT (unlike the reverse) will not undermine patients’ safety but rather introduce unnecessary caution.
Before Yi is observed, the optimal prediction for Yi based on the animal data is
ηˆi = arg max
η∈{0,1}
1∑
y˜=0
U(y˜, η)P(Yi = y˜), (9)
and we will take these optimal predictions for comparison with the observed human data.
Fouskakis and Draper [29] suggest a metric that quantifies the discrepancy between predicted and
actual values needs to be defined for assessing the accuracy of a model’s prediction. We now adapt this
idea to develop a measure of commensurability, which we re-evaluate at each interim analysis of the phase
I trial and use to dynamically choose the prior mixture weights for the new patient cohort in (7). We
measure the consistency of the preclinical and human data by the average utility of the optimal predictions
derived from animal data, taking averages across a suitable dosing range. We now describe in more detail
the measure of commensurability.
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For h ≥ 2, suppose we are at the (h − 1)th interim analysis when cohort (h − 1) has been treated
and observed. We want to look ahead to define the weight w(h) that will define the mixture prior used to
analyse the human data accrued up to cohort h. Let D(h−1) ⊆ D contain all the doses that have been tested
by this stage. For each di ∈ D(h−1), we summarise the total number of patients who have: a) received
dose di by cohort (h − 1); and b) were predicted toxicity outcome ηˆ = `; and c) experienced outcome
y˜ = s as n
(h−1)
i,`s . We then define the predictive utility of the preclinical information per administered dose
di ∈ D(h−1) as:
c
(h−1)
i =
∑1
`=0
∑1
s=0 u`sn
(h−1)
i,`s∑1
`=0
∑1
s=0 n
(h−1)
i,`s
for di ∈ D(h−1) (10)
where the denominator is the maximum utility that would be achieved if all predictions were correct.
Clearly c
(h−1)
i only measures the predictive utility of the animal data based on outcomes from the first
(h − 1) patient cohorts and on one dose. To measure the predictive utility of the animal data on all
‘interesting’ doses we define T (h−1) ⊆ D(h−1) as the set of doses administered by interim analysis (h− 1)
which are not more than one dose level lower than the current posterior estimate of the target dose.
Therefore, T (h−1) comprises tested doses in the neighbourhood (i.e. within one dose level) of the current
MTD estimate, as well as all other tried doses which are estimated to have a DLT risk exceeding Γ. The
current estimate of the MTD is based on the posterior formed by updating the mixture prior µ
(h)
0 (θ|xA)
with human data from cohorts 1, . . . , h − 1. Then, we measure the commensurability of the animal and
human data by averaging c
(h−1)
i across di ∈ T (h−1), that is,
κ(h−1) =
1
|T (h−1)|
∑
{i:di∈T (h−1)}
c
(h−1)
i , (11)
where |T (h−1)| is the number of doses in T (h−1). Taking averages across T (h−1) rather than D(h−1) can
be thought of as an *ad-hoc* constraint, but one which we apply in case averaging over very safe doses
leads to measures of κ(h−1) artificially biased upwards. To explain why this bias might arise, we note
that prior to starting the trial, we usually define D to include doses thought to be very safe based on
the preclinical data. At these safe doses, even if there were differences between the DLT risk predicted
from animal data and the true human risk, these differences would likely be small (in absolute terms)
and unlikely to manifest themselves in discrepancies between the optimal predictions and observed human
DLT outcomes. Therefore, the value of c
(h−1)
i for these low doses would be expected to be close to 1,
even in the presence of a prior-data conflict. The quantity κ(h−1) is used to determine the mixture weight
shown in (7) and thus the prior that will be used to analyse data accrued up to cohort h.
4.2 Choosing an appropriate tuning parameter
When using κ(h−1) to calculate w(h) in (7), we must bear in mind that κ(h−1) will be a noisy measure of
the predictive utility of the animal data, particularly in the early stages of the phase I trial when few doses
have been tried and few patients have been treated. As more data accrue, the assessment of predictive
utility becomes more convincing. To reflect this, rather than set w(h) = κ(h−1), we propose discounting
κ(h−1) according to a power law relationship, with
w(h) =
{
κ(h−1)
}λ(h−1)
for h = 2, . . . ,H (12)
where λ(h−1) is a time-dependent tuning parameter and λ(1), . . . , λ(H−1) ≥ 1 are a decreasing sequence of
powers. We consider two approaches for defining each λ(h). For any choice of λ(h), a weight w(h) = 1 will be
attributed to the informative prior component in (7) if preclinical data correctly predict all DLT outcomes
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in humans in the first (h− 1) cohorts. A simple proposal is to relate λ(h−1) to the trial information time,
that is,
λ(h−1) =
√
N/n(h−1) (13)
where N and n(h−1) are the maximum sample size and the number of patients recruited in the first (h−1)
cohorts, respectively. A similar power law function, linking the exponent with the trial information time,
has been used in a different context by Thall and Wathen [38] for response adaptive randomisation schemes.
Suppose di? ∈ D is recommended for use in cohort h. We also consider defining λ(h−1) to capture how
noisy our estimate of the predictive utility of the animal data for dose di? is. Let ηˆi? denote the optimal
prediction from animal data for the outcome of a patient on dose di? , and H be the maximum number of
cohorts planned for the phase I trial. Before cohort h is treated, both c
(h)
i? and c
(H)
i? are random variables.
To calculate the standard deviation of c
(h)
i? , we note that given a prior prediction ηˆi? = 0 (ηˆi? = 1)
the predictive utility can take values of either u00 or u10 (u01 or u11), with probabilities Pr(Yi? = 0) and
Pr(Yi? = 1), which can be set equal to their current posterior modal estimates. In contrast, computing the
standard deviation of c
(H)
i? is less straightforward. We can estimate it using simulation, setting P(Yi? = 1)
equal to the current posterior modal estimate of the DLT risk on dose di? . We then simulate the binary
outcomes of patients in each future cohort h, . . . ,H, assuming all future patients receive dose di? , and
calculate c
(H)
i? . We repeat this process 5,000 times and calculate the empirical standard deviation of the
simulated values of c
(H)
i? . We define λ
(h−1) as:
λ(h−1) =
σ{c(h)i? }
σ{c(H)i? }
, (14)
This reflects how noisy c
(h)
i? is compared with c
(H)
i? , which will be calculated based on data from the
(N − n(h−1)) patients to be recruited, given the data currently accrued from cohorts 1, . . . , h − 1. This
definition of λ(h−1) implicitly reflects the trial information time, since λ(h−1) is large in the early stages
of the trial and converges towards 1 as the trial progresses. In Section 6, we will compare the operating
characteristics of dose-escalation procedures using λ(h−1) as defined in (13) and (14).
5 Design and analysis of the example trial incorporating animal data
In this section, we illustrate how our proposed approach can be used to incorporate preclinical information
into a phase I dose-escalation study. Here, we define the target dose as one associated with a DLT risk of
Γ = 0.25.
5.1 Prior distributions based on preclinical information
We return to the AUY922 example described in Section 2. For illustrative purposes, we suppose that 0.1
and 2.7 mg/kg have each been tested in 30 dogs, of which 1 and 17 experienced DLTs, respectively. Using
allometric scaling, standardising body weight (BW) by body surface area (BSA), one can calculate the
human doses equivalent to 0.1 and 2.7 mg/kg in dogs as:
Equivalent human dose (mg/m2) = Animal dose (mg/kg)×
(
BW
BSA
)
Animal
,
where the right hand side translation factor, defined by BW and BSA, appropriate for dogs is (10/0.5),
as specified in the FDA draft guideline Estimating the Maximum Safe Starting Dose in Initial Clinical
Trials for Therapeutics in Adult Healthy Volunteers [1]. Thus, the equivalent human doses are 2 mg/m2
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Figure 2: Summaries of priors based on preclinical information. Panel A shows median and 95% CI of the marginal prior distributions
for the probability of toxicity in blue bars, together with the fitted probabilities in pink dashed lines from the bivariate normal prior
pi0(θ | xA) found with our optimiser. Panel B gives an overview about interval probabilities, where the background red curve indicates
the prior medians for probability of toxicity per dose. Panel C presents prior densities for the risks of toxicity at candidate starting
doses.
(labelled as dose d−1) and 54 mg/m2 (labelled as dose d0), with corresponding risks of toxicity p−1 and p0
in humans. We summarise the dog data as prior distributions p−1 ∼ Beta(1, 29) and p0 ∼ Beta(17, 13).
Recall that for the AUY922 phase I trial, D = {2, 4, 8, 16, 22, 28, 40, 54, 70} mg/m2. The human
equivalent doses for our preclinical data happen to lie in D. Assuming the human dose-toxicity rela-
tionship follows Model (2), we can follow steps (i) and (ii) in Section 3 to compute the 2.5th, 50th and
97.5th percentiles of the marginal prior distributions of p1, . . . , p9 and search to find a bivariate normal
approximation to the prior distribution of θ|xA which is given by:
θ | xA ∼ BVN
((−0.524
0.147
)
,
(
0.151 −0.008
−0.008 0.001
))
. (15)
Figure 2A compares the percentiles of the marginal priors with the fitted percentiles corresponding to
the bivariate normal distribution defined above. From Figure 2A we see that our hypothetical data on
60 dogs suggest that doses 16 and 22 mg/m2 have a risk of toxicity in humans close to the target level
of 0.25. Figures 2B – 2C summarise marginal prior distributions for p1, . . . , p9 calculated based on the
bivariate normal approximation to θ | xA given in (15). Figure 2B summarises each marginal prior by
three interval probabilities: (i) the probability of underdosing, said to occur when pi ∈ [0, 0.16); (ii) the
probability that pi lies in the target interval [0.16, 0.33); and (iii) the probability of overdosing, said to
occur when pi exceeds 0.33 [23]. Figure 2C presents the prior probability density curves for the lowest
doses in D. In our illustrative example, we set dose 4 mg/m2 as the starting dose for the phase I trial as
it appears to be safe with P(p2 < 0.1 | xA) = 0.825.
To evaluate the effective sample size (ESS) of the marginal prior distribution for pi implied by pi0(θ |
xA), we approximate it by a Beta(a, b) distribution with matching first and second moments. The ESS
is then (a + b) [32]. Table 2 lists prior ESSs for our hypothetical example. The preclinical data provide
information on the DLT risks on low doses equivalent to that which would be obtained from 16.4 –
20.1 humans. This prior information may overwhelm data from a small phase I trial. Therefore, it is
important to see whether our approach for dynamically leveraging animal data to learn about parameters
of a dose-toxicity relationship leads to a dose-escalation procedure with sensible operating characteristics,
particularly when there is a prior-data conflict. In the next Section, we use hypothetical data examples
to explore the behaviour of dose-escalation procedures based on our proposed priors for θ.
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5.2 Hypothetical data examples
From Figure 2B, we see that ahead of the phase I trial, doses up to 16 mg/m2 comply with the escalation
criterion defined in (1) if probabilities are based on the robust prior in (7) with h = 1 and w(1) = 1.
We analyse data from the first human cohort setting w(1) = 1 because a priori we believe the starting
dose determined from preclinical information is safe, meaning there would be little chance of observing
a conflict between the predicted human outcome (of no DLT) and the observed human outcomes. Dy-
namic updating of the prior mixture weight is implemented from the first interim analysis and onwards,
when accumulated human toxicity data is compared with the prior predictions obtained from animal data.
We simulated three data examples, where there is (i) a negligible prior-data conflict; (ii) a conflict
that the dog data under-estimate the DLT risk in humans; and (iii) a conflict that the dog data over-
estimate the DLT risk in humans. Dose escalation trials follow the BLRM procedure outlined in Section
2, implemented at each interim analysis (h− 1), h = 2, . . . ,H, using the mixture prior for θ, µ(h)0 (θ | xA),
defined in Section 3 with empirical weights reflecting the predictive utility of the dog data with a tuning
parameter of the form shown in (14). Patients were recruited in cohorts of size three and each hypothetical
trial can recruit a maximum of, for example, 11 cohorts. Once responses are available for all patients in
each cohort h, h = 1, . . . ,H, the prior is updated using Bayes Theorem based on all available human data
from cohorts 1, . . . , h to obtain the posterior:
µ(h)(θ | xA,x(h)H ) = w(h)∗ · pi(h)(θ | xA,x(h)H ) + (1− w(h)∗ ) ·m(h)(θ | x(h)H ), (16)
where x
(h)
H denotes the human data from the first h cohorts and w
(h)
∗ denotes the posterior mixture weight
attributed to the posterior pi(h)(θ | xA,x(h)H ), updated from pi0(θ | xA). Interim dose recommendations
are based on µ(h)(θ | xA,x(h)H ). We fit our Bayesian model with a robust mixture prior using Markov
chain Monte Carlo. The OpenBUGS [39] code for implementation is provided in Appendix C.
Figure 3 presents the dosing trajectory and evolution of the prior mixture weight attributed to
pi0(θ | xA) for the three data examples. Looking across the three hypothetical trials, we see that the
first discrepancy between the human data and their prior predictions occurs in the first cohort of data
example 2 and the fourth cohort of data examples 1 and 3. As noted in Section 4.1, a disagreement
between predictions and observed data could take a few cohorts to emerge, even when there is a conflict
between the true human dose-toxicity curve and predictions based on the animal data. The prior mixture
weight on pi0(θ | xA) decreases immediately from the value of 1, after the first disagreement has been
observed. Looking across all three data examples, the prior mixture weight typically plateaus or increases
slightly over the last couple of cohorts. This is because the predictive utility measure κ(h−1) looks at the
commensurability of the human and animal data, and is unlikely to vary substantially over the final stages
of the trial, while the tuning parameter λ(h−1) reduces to 1 as the trial progresses.
We focus now on data examples 2 and 3, to explore how the prior mixture weights evolve in the
presence of a prior-data conflict. In data example 2, the prior mixture weight that will be used to analyse
data accrued from the first fourth cohorts, w(4), increases to 0.767 after the rapid initial discounting of
the preclinical information, due to correct predictions of outcomes in cohorts 2 and 3 on the two lowest
doses. However, all three patients in cohort 4 administered 8 mg/m2 experience toxicities, outcomes which
the animal data wrongly predict as no DLTs. In response to this, w(5) drops to 0.083. Data example 3
shows how the procedure reacts to a data-conflict when the DLT risks in humans are much lower than
predicted by the animal data. In cohorts 4 and 5 assigned 22 mg/m2 and 28 mg/m2, respectively, no
DLTs are observed which contradicts the prior predictions based on animal data. Consequently, the prior
weights used for analysis at next interim analyses drop to w(5) = 0.533 and w(6) = 0.250. With the
lower prior weight w(5), the posterior weight w
(5)
∗ = 0.167, and this reduced borrowing from animal data
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Figure 3: Trajectory of dose recommendations (Panel A) and dynamic update of mixture weight attributed to preclinical information
(Panel B) during the course of each hypothetical data example.
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resulted in an escalation to dose 54 mg/m2, at which one out of three patients was observed with a DLT.
A de-escalation to 40 mg/m2 then took place, and the estimate of the target dose eventually converged
at this dose level. Finally, we note that using our approach leads to a compromise between full pooling
and complete discarding of preclinical animal data. Results of these assessments are available in Figure
S1 in the Web-based Supplementary Materials.
5.3 Specifying a run-in period
As was illustrated in Section 5.2, the methodology described in Sections 3 and 4 tends to implement full
borrowing of preclinical information in the early stages of the phase I trial when human toxicity outcomes
at low doses can be correctly predicted. However, it is counterintuitive that we should assign full weight
to the preclinical data in the early stages of a trial when few human data are available to assess com-
mensurability. This is particularly true since we know the agreement between prior predictions, based on
animal data alone, and the observed human data may be an artefact of starting the trial with very safe
doses rather than a reflection of a genuine agreement. If the true dose-toxicity relationship in humans
has a very steep slope, placing full weight on the animal prior could lead to overly aggressive escalation
decisions and unexpected DLTs.
To this end, we consider a constrained version of our approach with a run-in period. We set the prior
mixture weight equal to 0 until the first discrepancy is observed in cohort h?. From interim analysis
(h? + 1) onwards, accumulated human data are then analysed with a mixture weight calculated as de-
scribed in Sections 3 and 4. Under this scheme, the dose-escalation trial begins basing interim decisions on
a weakly informative prior m0(θ). To reach a fair conclusion about the impact of having a run-in period,
we present three new data examples in Figure 4 where observations are sampled without replacement from
the same simulated datasets used to create the corresponding data examples in Figure 3. For instance,
focusing on data example 1, the first patient assigned 28 mg/m2 in Figure 3 will have the same simulated
toxicity outcome as the first patient assigned 28 mg/m2 in Figure 4.
Implementing the run-in period has no impact on data example 2, since the first conflict between
the animal predictions and the human outcomes occurred in cohort 1. For data examples 1 and 3, we
notice that dose escalation decisions tend to be less conservative when using the run-in period, especially
in the early stages of the simulated trials, leading to different interim dose recommendations, as shown
in Figure 4. By the end of each simulated trial implementing the constrained version of our approach,
we observed the prior mixture weights w(11) are equal to the values obtained when we implement the
unconstrained version. This is due to (i) our way of simulating the human toxicity data, which ensures
the same likelihood of the human toxicity across our illustrative examples presented in Figures 3 and 4,
and (ii) the fact that the prior mixture weight is dynamically determined based on the compatibility of
preclinical and clinical trial data.
6 Simulation study
6.1 Basic settings
We continue with our motivating example from Sections 2 and 5, and evaluate the operating characteristics
of dose-escalation trials designed and conducted basing inferences on the mixture prior described in Sec-
tions 3 and 4 with empirical decision-theoretic weights. Comparisons are made with Bayesian procedures
basing inferences on mixture priors with fixed weights. We consider:
• Procedure A: Bayesian mixture prior with dynamic decision-theoretic weights; no run-in period
• Procedure B: Bayesian mixture prior with dynamic decision-theoretic weights; run-in period
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Figure 4: Trajectory of dose recommendations (Panel A) and dynamic update of mixture weight attributed to preclinical information
(Panel B) during the course of each hypothetical data example with a two-stage design, with a run-in period characterised in the first
stage and dose-escalation procedure driven by a mixture prior in the second stage.
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• Procedure C: Bayesian mixture prior with w(h) = 0.5 for all h; no run-in period
• Procedure D: Bayesian informative prior, that is, w(h) = 1 for all h; no run-in period
• Procedure E: Bayesian weakly informative prior, that is, w(h) = 0 for all h
Procedures A and B are implemented using expression (14) to calculate the λ tuning parameters. We
specify a fixed weight of 0.5 for Procedure C, as we speculate this will ensure the mixture prior has heavy
enough tails to adequately deal with most prior-data conflicts. We use the optimal non-parametric design
(O’Quigley et al., 2002) as a benchmark for comparison.
We assume the data on 60 dogs described in Section 5.1 are available prior to the phase I clinical
trial. To evaluate how rapidly procedures react to a prior-data conflict, we simulate small phase I trials
recruiting up to seven cohorts of three patients, with doses in D available for evaluation. As explained
in Section 5.1, patients in cohort 1 are assigned the dose 4 mg/m2. Interim analyses are performed
incorporating both animal and human toxicity information the dose for the next patient cohort is selected
according to a variant of criterion (1) such that
d
(h)
sel = max{di ∈ D : Pr(pi ≥ 0.33 | xA,x(h−1)H ) ≤ 0.25},
with the same constraint on a maximum two-fold escalation in dose. Trials end either when all 21 patients
have been treated and observed, or at any interim analysis h if Pr(p1 ≥ 0.33 | xA,x(h)H ) > 0.25. These
two subsets of simulated trials will be referred to as completed or stopped early trials, respectively.
Phase I trials are simulated under the eight human toxicity scenarios shown in Table 3. In Scenario
3, the human DLT risk on each dose is consistent with the prior median estimate obtained from the
dog data, where these estimates are illustrated in Figure 2A and were derived assuming the dose-toxicity
relationship in humans follows a logistic regression model. In none of the scenarios were the human DLT
risks derived from a logistic regression model. For all Bayesian procedures A–E, estimates of operating
characteristics are based on 1000 simulated trials per toxicity scenario.
Let p˜i denote the posterior median DLT risk for di ∈ D recorded on completion of the trial. At the
end of a completed trial, we declare the target dose to be
dˆM = arg min
di∈Dc
|p˜i − 0.25|,
where Dc ⊆ D comprises all doses that have been administered to humans during the trial and which
satisfy safety criterion (1). For each scenario, we report the percentage of simulated trials stopped early for
safety without selecting a target dose, and the percentage of simulated trials which are completed declaring
dose di as the target dose, for i = 1, . . . , 9. We are particularly interested in comparing procedures A –
E in terms of the percentage of early stopping in an overly toxic scenario, and the probability of correct
selection (PCS) in scenarios where we expect the phase I trial will end with identification of an MTD. We
also report the average number of patients allocated to each dose across the 1,000 simulated trials.
6.2 Results
Figure 5 visualises the operating characteristics of simulated phase I dose-escalation trials (using u01 =
0.6), in which inferences were made using Procedures A – E. Comprehensive numerical results are pre-
sented in Supplementary Table S1, along with results for the case where we set u01 = 0.2. Versions of our
results using expression (13) as a tuning parameter for the weights in Procedures A and B are provided
in Figure S2 of the Supplementary Materials.
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Figure 5: Operating characteristics of phase I clinical trials designed using the dose-escalation Procedures A - E. The vertical black
line indicates the true MTD in humans in each simulation scenario. ? indicates the trial was stopped early for safety. Proportions and
averages are calculated aggregating across 1000 simulated trials in each scenario.
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Figure 5 visualises the operating characteristics of simulated phase I dose-escalation trials (using
u01 = 0.6), in which inferences were made using Procedures A – E. Comprehensive numerical results are
presented in Supplementary Table S1, along with results for the case where we set u01 = 0.2. Versions
of our results using expression (13) as a tuning parameter for the weights in Procedures A and B are
provided in Figure S2 of the Supplementary Materials.
Focusing on procedures A and B using a mixture prior with empirical decision-theoretic weights, we
can draw conclusions about the value of incorporating a run-in period. We see that Procedures A and
B perform similarly in almost all scenarios except Scenario 8. In this scenario, the dog data over-predict
the human DLT risk: the drug is in fact very safe in humans with the highest dose being the MTD.
Procedure A, which considers leveraging animal data from the outset of the trial, thus tended to be more
cautious in the early stages, with more patients treated at low, very safe, doses. The procedure is slow
to discount the animal data because they predict no DLTs at low doses up to 16 mg/m2. In contrast,
Procedure B (with a run-in period) allowed quicker escalation than Procedure A, since the animal data
are only leveraged after the first disagreement between animal predictions and human outcomes has been
observed. By this point, we had typically escalated up to higher doses, where the prior-data conflict was
more likely to manifest itself in the observed data. This explains why, in Panel (ii), on average only 1.3
out of 21 patients were allocated to 70 mg/m2 by Procedure A, while slightly more (2.4 out of 21) were
allocated to the true MTD by Procedure B in Scenario 8. Panel (i) shows that the PCS for Procedure B in
Scenario 8 is 33.8% compared with 20.3% for Procedure A. We observe that this difference is even larger
if we take a smaller utility such as u01 = 0.2. A similar line of reasoning explains differences between
Procedures A and B in Scenario 6.
Procedure E selects dose 70 mg/m2 as the MTD for 58.0% of the simulated trials in Scenario 8.
This reveals a weakness of our methodology in situations where there are differences between the prior
dose-toxicity relationship and the true curve in humans, but these are too small to result in discrepancies
between the prior predictions and the human outcomes. Implementing our approach with a run-in period
improves operating characteristics as it enables us to escalate up to higher doses where there is a greater
chance of observing a disagreement between animal predictions and human responses.
Comparing Procedures B and C, we see that the former leads to an increase in PCS from 38.1% to
48.7% in Scenario 3, when the preclinical and human data are commensurate. In other scenarios, both
procedures have similar operating characteristics, such as PCS and the number of patients treated with
the MTD. In results not shown here, we found that in scenarios where there is a prior-data conflict,
Procedure B achieves higher PCS than versions of Procedure C with fixed prior mixture weights set equal
to a constant between 0.5 and 1. Comparing Procedures B, D and E, we see that Procedure B offers
a compromise between incorporating the preclinical data with no down-weighting and no leveraging of
animal data at all. While Procedure D achieves maximum PCS in Scenarios 2 – 4 when preclinical and
human data are commensurate, it performs very poorly in Scenarios 6 and 8 when there is a prior-data
conflict; the situation is reversed for Procedure E. However, Procedure B maintains reasonable operating
characteristics over a range of scenarios.
Figure S2 of the Supplementary Materials summarises operating characteristics of Procedures A and
B using expression (13) for the tuning parameter used to discount our measure of predictive utility when
calculating w(h). Results are similar to those shown here. We have also run simulations setting the
maximum trial sample size as 33 (i.e., 11 patient cohorts) and 45 (i.e., 15 patients cohorts). Similar
conclusions are drawn, with the exception that differences between Procedures A and B for the PCS in
Scenario 8 diminish with increasing maximum trial sample size. This is because as the number of patients
increases, the trial can escalate up to the highest dose when using Procedure A before the maximum
sample size has been reached. On the other hand, if we had more informative animal prior, say, the
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variances of dose-toxicity parameters suggested by preclinical information are smaller, than those of the
one currently in use for illustration, adopting Procedure B becomes more advantageous than Procedure
C for its assessment of commensurability to determine the amount of information to borrow.
7 Discussion
The question of using historical data in a new clinical trial has been discussed elsewhere, but in the context
of leveraging preclinical information into a phase I first-in-man trial, there are unique circumstances to be
taken care of. Indeed, the challenge is to address potential prior-data conflicts, arising from the intrinsic
difference between toxicity of a drug to animals and humans, which emerge in a sequential trial planned
with a small sample size. Here, “small” is meant in relation to the prior effective sample size. In this
paper, we have outlined solutions for translating preclinical animal toxicity data recorded on their original
scale to make inference on the toxicity in humans, especially at the doses available to be administered to
patients, and proposed a Bayesian decision-theoretic approach to using such information in an ongoing
phase I dose-escalation trial in an adaptive way. Commensurability of the translated animal data with
the newly accrued toxicity data is successively assessed to determine a sensible amount of borrowing. A
formal measure to inform the commensurability was defined in terms of how correct the prior predictions
based on animal data can be by comparing them with the observed outcomes available later on. Incorrect
predictions will be penalised by giving a small utility value to quickly discount animal data during the
course of a phase I clinical trial.
Illustrative examples and the simulation study show that the proposed methodology leads to sensible
borrowing of preclinical information to aid decision making in a phase I clinical trial, and is responsive
to a prior-data conflict emerges any time during the trial. We note robust inference does not seem to
be possible in a most basic kind of borrowing based on the Bayes Theorem that incorporates preclinical
information as what it is entirely. Conventionally, if desired to be used in a new phase I clinical trial,
animal data would usually be down-weighted to contain least amount of information in the beginning so as
to avoid overriding data from the trial. Whereas, our approach provides a possibility to borrow strength
from animal data adaptively. It is a developed version of mixture prior with feasible mid-course modifi-
cation of the prior mixture weight. As we have observed from the simulations comparing our approach
with its origin, potential benefit includes the increased borrowing in cases of prior-data consistency and
the capability of discounting any inconsistent prior even quicker.
When formulating the research problem, we have assumed that animal data were available from two
interesting doses, as quite a few preclinical animal studies are conducted to evaluate the toxicity on a
qualitative basis. However, this should not be taken as a restriction of applying the proposed methodology.
When richer animal data are available from a number of preclinical in vivo studies performed in one
species, information may be synthesised using meta-analysis to derive the prior predictive distribution for
probability of toxicity per dose in humans, and used to make optimal prior predictions for assessing the
commensurability of the synthesised animal data with human toxicity data. The discussion of using animal
data collected from preclinical studies involving multiple animal species is beyond the scope of this paper.
In such a more challenging case, we may wish to allocate larger weights to species that are more relevant
to humans than others, whereas the decision-theoretic approach proposed at present does not allow us to
draw the distinction. This is where we look toward for the future work to extend the methodology. We are
also currently pursuing the use of animal pharmacokinetic information by establishing a Bayesian dose-
exposure-toxicity model in light of the increasing interest in better understanding and characterisation of
dose-toxicity relationship [40, 41].
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Table 1: Cross-tabulation of utilities for the predicted versus actual human binary DLT outcomes.
Observation (y˜)
No-DLT DLT
Prior prediction (ηˆ) No-DLT u00 u10
DLT u01 u11
Table 2: Effective sample sizes of marginal prior distributions for risk of toxicity based on animal data summarised by pi0(θ|xA).
Dose (mg/m2)
d1 d2 d3 d4 d5 d6 d7 d8 d9
2 4 8 16 22 28 40 54 70
Prior means 0.034 0.065 0.120 0.211 0.267 0.314 0.393 0.463 0.526
Prior std dev. 0.022 0.038 0.061 0.089 0.101 0.109 0.117 0.119 0.118
ESS 67.1 41.7 27.6 20.1 18.2 17.2 16.5 16.4 16.9
a 2.3 2.7 3.3 4.2 4.9 5.4 6.5 7.6 8.9
b 64.8 39.0 24.3 15.9 13.3 11.8 10.0 8.8 8.0
Table 3: Simulation scenarios for the true probability of DLT in humans. The figure in bold indicates the dose closest to the true MTD.
Dose (mg/m2)
d1 d2 d3 d4 d5 d6 d7 d8 d9
2 4 8 16 22 28 40 54 70
Scenario 1 0.11 0.25 0.35 0.41 0.47 0.52 0.58 0.63 0.70
Scenario 2 0.08 0.16 0.25 0.35 0.42 0.45 0.53 0.60 0.70
Scenario 3 0.02 0.05 0.14 0.25 0.35 0.42 0.51 0.60 0.68
Scenario 4 0.03 0.05 0.10 0.16 0.25 0.32 0.40 0.48 0.55
Scenario 5 0.001 0.005 0.03 0.10 0.16 0.25 0.38 0.50 0.60
Scenario 6 0.01 0.02 0.05 0.08 0.11 0.14 0.25 0.37 0.47
Scenario 7 0.35 0.42 0.60 0.75 0.82 0.88 0.91 0.94 0.97
Scenario 8 0.001 0.005 0.01 0.02 0.04 0.05 0.10 0.16 0.25
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Appendix
A. Deriving the marginal probability density function for pj
We consider to express the preclinical animal data for predicting the risks of toxicity at human doses
as pseudo-data. Thus, at these two pseudo dose levels j = −1, 0, uncertainty surrounding the risks
of toxicity pj could be described with Beta distributions with parameters tj and vj . The joint prior
probability density function (pdf) of p−1 and p0 is given by
f(p−1, p0) =
0∏
j=−1
p
tj−1
j (1− pj)vj−1
B(tj , vj)
,
where B(·, ·) is the beta function.
Given the logistic dose-toxicity model, the joint pdf f(p−1, p0) can be expressed in terms of the model
parameters θ1 and θ2 via Jacobian transformation,
h(θ1, θ2) = f(p−1, p0)× ∂(p−1, p0)
∂(θ1, θ2)
. (17)
From
log
(
pj
1− pj
)
= θ1 + exp(θ2) log(dj/dRef),
we can easily derive
∂pj
∂θ1
= pj(1− pj) and ∂pj
∂θ2
= pj(1− pj) exp(θ2) log(dj/dRef).
Thus, the joint prior pdf of θ1 and θ2 can be written as
h(θ1, θ2) = exp(θ2)
∣∣∣∣log(d−1d0
)∣∣∣∣× 0∏
j=−1
p
tj
j (1− pj)vj
B(tj , vj)
,
where the two pseudo doses d−1 and d0 correspond to the lowest and highest human doses in our context.
Substituting the pj with the logistic model parameters, we can write this joint prior pdf more explicitly:
h(θ1, θ2) = exp(θ2)
∣∣∣∣log(d−1d0
)∣∣∣∣× 0∏
j=−1
[1 + exp(−zj)]−tj [1 + exp(zj)]−vj
B(tj , vj)
,
where zj = θ1 + exp(θ2) log(dj/dRef).
By applying Jacobian transformation again, we can further derive the joint prior pdf of pi and θ2; for
i = 1, . . . , I,
gi(pi, θ2) = h(θ1, θ2)× ∂(θ1, θ2)
∂(pi, θ2)
.
With  θ1 = log
(
pi
1− pi
)
− exp(θ2) log(di/dRef)
θ2 = θ2
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we can write
∂θ1
∂pi
=
1
pi(1− pi) ,
∂θ1
∂θ2
= 0,
∂θ2
∂pi
= 0,
∂θ2
∂θ2
= 1,
such that
gi(pi, θ2) = h(θ1, θ2)× ∂(θ1, θ2)
∂(pi, θ2)
,
=
1
pi(1− pi) · exp(θ2)
∣∣∣∣log(d−1d0
)∣∣∣∣× 0∏
j=−1
[1 + exp(−zji)]−tj [1 + exp(zji)]−vj
B(tj , vj)
,
where zji = θ1 + exp(θ2) log(dj/dRef).
Because θ1 in zj can be expressed with θ2 and pi given the logistic regression model that
zji = log
(
pi
1− pi
)
+ exp(θ2) log
(
dj
di
)
,
the joint prior pdf gi(pi, θ2) can therefore be parameterised with only pi and θ2. The marginal probability
density function for pj , the risk of toxicity at dose di, i = 1, . . . , I, can then be derived by integrating out
the nuisance parameter θ2:
fi(pi) =
∫
gi(pi, θ2)dθ2.
B. Implied percentiles on the scale of pj, given a bivariate normal prior
for θ
For log
(
p
1−p
)
= z, the 95% credible interval for p is bounded by
(
exp(zL)
1+exp(zL)
, exp(zU )1+exp(zU )
)
should we have
known the lower and upper limits of z. Here z can be seen as a transformed random variable, as following
our parameterisation z = θ1 + exp(θ2) log(d/dRef).
B.1. The first two moments of the transformed random variable z
The expectation for z is E(z) = E[θ1 + exp(θ2) log(d/dRef)] = E(θ1) + log(d/dRef)E(exp(θ2)). By Taylor
expansion, we know
E(exp(θ2)) ≈ exp(E(θ2)) + 1
2
exp(E(θ2)) ·Var(θ2)
= exp(E(θ2))[1 +
1
2
Var(θ2)]
≈ exp
[
E(θ2) +
1
2
Var(θ2)
]
.
The last step follows the Taylor approximation exp(x) ≈ 1 + x, which works well for small x. Having
x = 12Var(θ2) leads to exp(E(θ2))[1 + x] ≈ exp(E(θ2) + x). Thus, the first moment for z is approximated
as
E(z) = E(θ1) + log(d/dRef) exp
[
E(θ2) +
1
2
Var(θ2)
]
. (18)
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Since z2 = θ21 + 2θ1 exp(θ2) log(d/dRef) + exp(2θ2)[log(d/dRef)]
2, the second moment is then given by
E(z2) = E(θ21) + 2 log(d/dRef) ·E(θ1 · exp(θ2)) + [log(d/dRef)]2 ·E(exp(2θ2))
= Var(θ1) + [E(θ1)]
2 + 2 log(d/dRef)[Cov(θ1, exp(θ2)) +E(θ1)E(exp(θ2))]
+ [log(d/dRef)]
2 ·E(exp(2θ2)),
(19)
while we have
[E(z)]2 = [E(θ1)]
2 + 2 log(d/dRef) ·E(θ1)E(exp(θ2)) + [log(d/dRef)]2[E(exp(θ2))]2.
Thus,
Var(z) = E(z2)− [E(z)]2
= Var(θ1) + 2 log(d/dRef) · Cov(θ1, exp(θ2))
+ [log(d/dRef)]
2[E(exp(2θ2))−E(exp(θ2))]2
= Var(θ1) + 2 log(d/dRef) · Cov(θ1, exp(θ2)) + [log(d/dRef)]2 ·Var(exp(θ2)).
(20)
For the Cov(θ1, exp(θ2)) in (20), with Stein’s Lemma, it holds that
Cov(θ1, exp(θ2)) = E(exp(θ2)) · Cov(θ1, θ2)
≈ exp
[
E(θ2) +
1
2
Var(θ2)
]
· Cov(θ1, θ2).
For the Var(exp(θ2)) in (20),
Var(exp(θ2)) = E(exp(2θ2))− [E(exp(θ2))]2
≈ exp(2E(θ2) + 2Var(θ2))− exp(2E(θ2) + Var(θ2))
= exp(2E(θ2) + Var(θ2)) · exp(Var(θ2))− exp(2E(θ2) + Var(θ2))
= exp(2E(θ2) + Var(θ2))[exp(Var(θ2))− 1].
B.2. The lower and upper limits of z
With (18) and (20), the lower and upper limits of z are
zL = E(z)− 1.96
√
Var(z),
zU = E(z) + 1.96
√
Var(z).
Obtaining the implied percentiles denoted by q′jk, we can then easily code up the optimiser used to find a
bivariate normal prior pi(θ) given the prior probabilities qjk obtained following steps described in Section
3.
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C. OpenBUGS code for implementation
model{
# sampling model
for(j in 1:Ncohorts){
lin[j] <- theta[1] + exp(theta[2])*log(doseH[j]/dRef)
logit(pTox[j]) <- lin[j]
NtoxH[j] ~ dbin(pTox[j], NsubH[j])
}
for(i in 1:MdoseH){
lin.star[i] <- theta[1] + exp(theta[2])*log(doseH[i]/dRef)
logit(pTox.star[i]) <- lin.star[i]
pCat[i, 1] <- step(pTox.cut[1] - pTox.star[i])
pCat[i, 2] <- step(pTox.cut[2] - pTox.star[i])
- step(pTox.cut[1] - pTox.star[i])
pCat[i, 3] <- step(1 - pTox.star[i]) - step(pTox.cut[2] - pTox.star[i])
}
theta[1:2] ~ dmnorm(thetaMu[which, 1:2], thetaPrec[which, 1:2, 1:2])
which ~ dcat(wMix[1:2])
# to monitor the exchangeability probability
# in the course of the new human trial
for(k in 1:2){
prob.ex[k] <- equals(which, k)
}
thetaMu[1, 1:2] ~ dmnorm(PriorA[1:2], thetaPrec[1, 1:2, 1:2])
cov.A[1, 1] <- PriorA[3]
cov.A[1, 2] <- PriorA[4]
cov.A[2, 1] <- cov.A[1, 2]
cov.A[2, 2] <- PriorA[5]
thetaPrec[1, 1:2, 1:2] <- inverse(cov.A[1:2, 1:2])
thetaMu[2, 1:2] ~ dmnorm(Prior.mw[1:2], thetaPrec[2, 1:2, 1:2])
cov.rb[1, 1] <- pow(Prior.sw[1], 2)
cov.rb[2, 2] <- pow(Prior.sw[2], 2)
cov.rb[1, 2] <- Prior.sw[1]*Prior.sw[2]*Prior.corr
cov.rb[2, 1] <- cov.rb[1, 2]
thetaPrec[2, 1:2, 1:2] <- inverse(cov.rb[1:2, 1:2])
}
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A. DATA EXAMPLES FOR NO BORROWING OR FULL POOLING OF ANIMAL DATA
In Section 5.2, we simulated three hypothetical phase I clinical trials to exemplify interim dose
recommendations, using the proposed method to leverage preclinical data without undermining
patients’ safety. Here, we show in Figure S1 how doses would have been recommended in an
alternative Bayesian dose-escalation procedure driven by either an operational prior m0(θ) or an
animal prior pi0(θ|xA).
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Figure S1: Trajectory of dose recommendations under alternative Bayesian dose-escalation procedures.
These new data examples presented in Figure S1 were simulated from the same parameter
settings used for those presented in Figure 3 of the main manuscript for a fair comparison: a vector
of binary outcomes on each dose were simulated and then sampled without replacement as each
new patient was assigned to a dose in the dose-escalation study. For example, looking at data
examples with the same label, the first patient receiving dose 28 mg/m2 in Figure 3 and Figure
S1, involved in different Bayesian dose-escalation procedures will have the same simulated binary
toxicity outcome. We may therefore observe what could have been the consequence by adopting
different priors in a Bayesian dose-escalation procedure.
From this comparison, we can see the impact of leveraging the preclinical data on decision
making in an adaptive phase I clinical trial. Using our approach leads to compromises between
1
full pooling and complete discard of preclinical animal data. In the simulated trials labelled with
data example 1, we observe that behaviours of the trial using our approach is similar with that
implememted with Bayesian approach fully incorporating animal data in the prior, as under this
prior-data consistency scenario a large prior mixture weight will be attributed to animal data
based upon our assessment of commensurability. Advantages of using our approach are also
evident in scenarios of a prior-data conflict: unlike a trial with animal data fully incorporated, less
patients were allocated with overly toxic dose 8 mg/m2 in data example 2, while more patients
will have chance to escalate to a true target dose which is dose 40 mg/m2 in data example 3.
B. NUMERICAL RESULTS OF ALL EVALUATE SCENARIOS
The performance of trials using BLRM-guided dose-escalation Procedures A – E are compared
with that of the optimal non-parametric benchmark design by [1]. The optimal design is defined
using the ‘complete’ toxicity profile of each patient, created by assuming there are Ji? clones of a
patient given doses spanning the dosing set Di? . A toxicity tolerance thereshold en is generated
from U[0, 1] for the nth patient, which determines the corresponding toxicity outcome at the jth
dose as
Rjn = 1(en ≤ pi? j), 1 ≤ n ≤ N, 1 ≤ j ≤ Ji? ,
where 1(·) is the indicator function. An unbiased estimate for pi? j is thus R¯j(N) = 1N ∑Nn=1 Rjn
for a trial of which the maximum sample size is N. Consequently, the estimated MTD under the
benchmark design is
dˆoptM = arg minj=1,...,Ji?
|R¯j(N)− 0.25|.
Improvements beyond this bound are not possible unless strong parametric assumptions are
made about dose-response relationships. In our context, we wish to quantify the gains that can
be made over the benchmark designs, in part due to borrowing strength from the preclinical data.
Table S1 provides a complete listing of all simulation results for analysis models defined in Section
6 and the optimal benchmark design.
C. ADDITIONAL SIMULATION RESULTS
We present additional results in Figure S2 from the simulation study, where λ(h−1) =
√
N/n(h−1)
together with u01 = 0.6 was used to compute the prior mixture weight w(h) attributed to the
informative preclinical component in the mixture prior. Each simulated trial has maximum 21
patients; that is, in total seven cohorts. Results show that Procedures A and B stipulating the
tuning parameter λ(h−1) =
√
N/n(h−1) work equally well as their variants stipulating λ(h−1) in
the form of (14) defined in the main manuscript. What has also been shown here in Figure S3 is
the results from another simulation study, where we set the maximum trial sample size to be 33
(i.e., 11 patient cohorts). With increase of trial sample size, differences between Procedures A and
B for the PCS in scenario 8. As was explained in the main manuscript, this is because we will
have chance to escalate to the highest dose when more information accrues from the current trial
to overcome the incompatible animal prior information.
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Figure S2: Operating characteristics of phase I clinical trials designed using the dose-escalation Procedures A - E, where the tuning
parameter is stipulated explicitly relating to the trial information time for Procedures A and B. The vertical black line indicates the
true MTD in humans in each simulation scenario.
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Figure S3: Operating characteristics of phase I clinical trials, setting the maximum trial sample size as 33 (i.e., 11 patient cohorts),
designed using the dose-escalation Procedures A - E. The vertical black line indicates the true MTD in humans in each simulation
scenario.
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Table S1: Comparison of the analysis models in terms of the percentage of selecting a dose as MTD at the end of the trials, percentage
of early stopping for safety, average patient allocation, and average number of patients with toxicity.
Sc. Design
% dose declared as MTD & average patient allocation
DLT N¯
di?1 di?2 di?3 di?4 di?5 di?6 di?7 di?8 di?9 None2 4 8 16 22 28 40 54 70
1 pTox 0.11 0.25 0.35 0.41 0.47 0.52 0.58 0.63 0.70
Optimal Sel 18.2 54.2 19.8 5.6 1.5 0.4 0.1 0 0
A u01 = 0.6 Sel 4.2 18.2 35.7 6.6 0.7 0.1 0 0 0 34.5
Pts 1.6 6.8 5.8 1.6 0.2 0 0 0 0 4.7 16.0
u01 = 0.2 Sel 4.2 18.2 35.8 6.4 0.8 0.1 0 0 0 34.5
Pts 1.6 6.8 5.8 1.5 0.2 0 0 0 0 4.7 15.9
B u01 = 0.6 Sel 3.8 18.8 36.0 5.6 1.0 0 0 0 0 34.8
Pts 1.5 6.6 6.0 1.5 0.1 0.1 0 0 0 4.6 15.8
u01 = 0.2 Sel 3.8 18.8 35.9 5.7 1.0 0 0 0 0 34.8
Pts 1.5 6.6 6.0 1.4 0.2 0.1 0 0 0 4.7 15.8
C Sel 5.7 26.0 28.5 4.4 1.3 0.4 0 0 0 33.7
Pts 0.9 7.0 6.6 1.4 0.1 0.1 0 0 0 4.8 16.1
D Sel 0 2.2 76.4 20.3 1.1 0 0 0 0 0
Pts 0 3.1 13.0 4.7 0.2 0 0 0 0 7.3 21.0
E Sel 9.7 31.0 20.7 2.4 1.3 0.7 0 0.1 0 34.1
Pts 2.2 7.2 4.9 1.1 0.1 0.2 0 0 0 4.3 15.7
2 pTox 0.08 0.16 0.25 0.35 0.41 0.45 0.52 0.58 0.63
Optimal Sel 4.3 28.1 39.8 20.3 4.9 1.7 0.7 0.1 0.1
A u01 = 0.6 Sel 1.4 9.5 45.6 22.7 4.4 0.8 0.1 0 0 15.5
Pts 1.0 5.4 7.8 3.6 0.7 0.1 0 0 0 4.5 18.6
u01 = 0.2 Sel 1.4 9.5 46.3 21.8 4.6 0.9 0 0 0 15.5
Pts 1.0 5.4 7.8 3.6 0.7 0.1 0 0 0 4.5 18.6
B u01 = 0.6 Sel 1.4 9.5 45.9 21.9 4.2 1.6 0 0 0 15.5
Pts 1.0 5.4 7.8 3.6 0.5 0.3 0.1 0 0 4.5 18.7
u01 = 0.2 Sel 1.4 9.5 46.0 21.4 5.2 0.9 0.1 0 0 15.5
Pts 1.0 5.4 7.8 3.6 0.6 0.3 0.1 0 0 4.5 18.8
C Sel 1.5 17.0 48.3 16.6 3.9 0.7 0.1 0 0 11.9
Pts 0.4 6.2 8.9 2.9 0.5 0.2 0 0 0 4.6 19.1
D Sel 0 0 49.3 45.7 5.0 0 0 0 0 0
Pts 0 3.0 9.3 8.1 0.6 0 0 0 0 5.8 21.0
E Sel 2.1 24.1 38.8 10.0 5.0 2.2 0.3 0.3 0.2 17.0
Pts 1.3 6.5 6.9 2.5 0.4 0.6 0 0.1 0 4.2 18.3
3 pTox 0.02 0.05 0.14 0.25 0.35 0.42 0.51 0.60 0.68
Optimal Sel 0 1.0 24.5 46.3 21.5 5.3 1.3 0.1 0
A u01 = 0.6 Sel 0 1.0 24.0 49.0 19.0 4.1 0.9 0.1 0 1.9
Pts 0.2 3.8 6.7 6.9 2.4 0.6 0 0 0 3.9 20.6
u01 = 0.2 Sel 0 1.0 24.9 47.1 21.2 3.9 0 0 0 1.9
Pts 0.2 3.8 6.8 7.0 2.5 0.4 0 0 0 4.5 20.7
B u01 = 0.6 Sel 0 1.0 23.9 48.7 19.4 4.3 0.8 0 0 1.9
Pts 0.2 3.8 6.7 7.0 1.8 1.1 0.1 0 0 4.0 20.7
u01 = 0.2 Sel 0 1.0 24.6 47.6 21.1 3.7 0.1 0 0 1.9
Pts 0.2 3.8 6.7 7.0 1.8 1.1 0.1 0 0 4.0 20.7
C Sel 0 1.8 34.5 38.1 17.1 6.2 0.7 0.2 0.1 1.3
Pts 0 3.9 7.9 5.9 1.7 1.2 0.2 0 0 4.0 20.8
D Sel 0 0 11.6 61.6 26.7 0.1 0 0 0 0
Pts 0 3.0 4.7 10.9 2.4 0 0 0 0 4.3 21.0
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Table S1 – Continued.
Sc. Design
% dose declared as MTD & average patient allocation
DLT N¯
di?1 di?2 di?3 di?4 di?5 di?6 di?7 di?8 di?9 None2 4 8 16 22 28 40 54 70
E Sel 0 4.0 39.3 26.8 17.5 8.8 1.5 0.5 0.4 1.2
Pts 0.4 4.2 7.6 5.2 1.3 1.9 0.1 0.2 0 3.9 20.9
4 pTox 0.03 0.05 0.10 0.16 0.25 0.32 0.40 0.48 0.55
Optimal Sel 0 0.4 6.7 23.8 37.5 20.7 8.5 2.1 0.3
A u01 = 0.6 Sel 0 0 9.4 34.6 34.3 15.2 4.4 0.4 0.3 1.4
Pts 0.2 3.6 5.2 6.5 3.4 1.6 0.1 0.1 0 3.2 20.7
u01 = 0.2 Sel 0 0 10.3 34.9 36.8 16.6 0 0 0 1.4
Pts 0.2 3.6 5.3 6.7 3.6 1.5 0 0 0 3.1 20.9
B u01 = 0.6 Sel 0 0 9.5 34.0 35.5 16.4 3.0 0.1 0.1 1.4
Pts 0.2 3.6 5.2 6.6 2.6 2.1 0.4 0 0.1 3.3 20.8
u01 = 0.2 Sel 0 0 10.1 35.7 37.3 13.8 1.1 0.5 0.1 1.4
Pts 0.2 3.6 5.2 6.5 2.8 2.0 0.4 0 0.1 3.3 20.8
C Sel 1.2 0 0.3 13.3 34.6 27.9 20.0 1.5 0.9 0.3
Pts 0 3.6 6.0 5.8 2.6 2.3 0.5 0 0.1 3.4 20.9
D Sel 0 0 0 2.0 43.6 53.7 0.7 0 0 0
Pts 0 3.0 3.6 9.7 4.6 0.1 0 0 0 3.2 21.0
E Sel 0 2.0 17.1 21.6 25.0 20.1 9.9 1.5 1.5 1.3
Pts 0.4 3.8 5.5 5.2 1.7 3.1 0.3 0.6 0.1 3.4 20.7
5 pTox 0.001 0.005 0.03 0.10 0.16 0.25 0.38 0.50 0.60
Optimal Sel 0 0 0.1 8.4 24.6 44.2 20.4 2.2 0.1
A u01 = 0.6 Sel 0 0 0.7 12.4 38.5 38.5 7.8 1.8 0.3 0
Pts 0 3.1 3.5 5.1 4.9 3.5 0.4 0.4 0.1 2.7 21.0
u01 = 0.2 Sel 0 0 0.8 11.8 43.2 44.2 0 0 0 0
Pts 0 3.1 3.5 5.3 5.4 3.7 0 0 0 2.5 21.0
B u01 = 0.6 Sel 0 0 0.7 13.6 38.8 40.3 6.1 0.1 0.4 0
Pts 0 3.1 3.5 5.3 3.6 4.3 1.1 0 0.2 2.9 21.0
u01 = 0.2 Sel 0 0 0.7 14.8 43.5 37.4 2.7 0.5 0.4 0
Pts 0 3.1 3.5 5.2 3.7 4.2 1.0 0 0.2 2.9 20.9
C Sel 0 0 1.2 16.3 32.4 41.1 6.7 1.2 1.1 0
Pts 0 3.1 3.7 5.3 3.2 4.3 1.1 0.1 0.2 2.9 21.0
D Sel 0 0 0 12.0 81.1 6.9 0 0 0 0
Pts 0 3.0 3.0 6.8 7.8 0.4 0 0 0 2.1 21.0
E Sel 0 0 2.5 11.0 28.7 35.3 17.9 1.7 2.9 0
Pts 0.1 3.1 3.7 5.0 2.0 5.2 0.7 1.1 0.1 3.1 21.0
6 pTox 0.01 0.02 0.05 0.08 0.11 0.14 0.25 0.37 0.47
Optimal Sel 0 0 0.6 3.2 7.6 15.1 49.5 20.6 3.4
A u01 = 0.6 Sel 0 0 1.4 7.5 25.1 37.5 20.4 6.4 1.3 0.4
Pts 0 3.2 3.9 4.8 3.9 3.6 0.6 0.7 0.2 2.1 20.9
u01 = 0.2 Sel 0 0 1.4 8.2 26.5 63.5 0 0 0 0.4
Pts 0 3.2 3.9 4.8 4.5 4.5 0 0 0 1.8 20.9
B u01 = 0.6 Sel 0 0 1.4 7.6 22.2 44.1 21.9 0.1 2.3 0.4
Pts 0 3.2 3.9 4.8 2.2 4.4 1.7 0.2 0.5 2.3 20.9
u01 = 0.2 Sel 0 0 1.4 8.5 27.0 46.4 10.6 3.5 2.2 0.4
Pts 0 3.2 3.9 4.8 2.5 4.1 1.8 0.2 0.5 2.3 21.0
C Sel 0 0 1.1 7.4 18.0 45.7 17.1 5.1 5.6 0
Pts 0 3.2 4.1 4.4 2.4 4.5 1.6 0.2 0.6 2.3 21.0
D Sel 0 0 0 9.8 73.6 16.6 0 0 0 0
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Table S1 – Continued.
Sc. Design
% dose declared as MTD & average patient allocation
DLT N¯
di?1 di?2 di?3 di?4 di?5 di?6 di?7 di?8 di?9 None2 4 8 16 22 28 40 54 70
Pts 0 3.0 3.1 6.4 7.8 0.7 0 0 0 1.7 21.0
E Sel 0 0.1 3.1 4.5 11.1 31.8 27.9 8.0 13.2 0.3
Pts 0.2 3.2 4.0 4.0 1.1 4.7 1.2 2.0 0.5 2.6 20.9
7 pTox 0.35 0.42 0.60 0.75 0.82 0.88 0.91 0.94 0.97
Optimal Sel 93.9 5.7 0.4 0 0 0 0 0 0
A u01 = 0.6 Sel 3.4 6.4 1.4 0 0 0 0 0 0 88.8
Pts 1.5 5.1 1.5 0.1 0 0 0 0 0 3.6 8.2
u01 = 0.2 Sel 3.4 6.4 1.4 0 0 0 0 0 0 88.8
Pts 1.5 5.1 1.5 0.1 0 0 0 0 0 3.6 8.2
B u01 = 0.6 Sel 3.4 6.4 1.4 0 0 0 0 0 0 88.8
Pts 1.5 5.1 1.5 0.1 0 0 0 0 0 3.6 8.2
u01 = 0.2 Sel 3.4 6.4 1.4 0 0 0 0 0 0 88.8
Pts 1.5 5.1 1.5 0.1 0 0 0 0 0 3.6 8.2
C Sel 4.1 6.9 0.7 0 0 0 0 0 0 88.3
Pts 1.0 6.1 1.5 0.1 0 0 0 0 0 3.9 8.7
D Sel 0.1 59.6 40.3 0 0 0 0 0 0 0
Pts 0 5.8 14.8 0.4 0 0 0 0 0 11.7 21.0
E Sel 6.0 5.1 0 0 0 0 0 0 0 88.9
Pts 2.1 4.6 1.0 0.1 0 0 0 0 0 3.3 7.8
8 pTox 0.001 0.005 0.01 0.02 0.04 0.05 0.10 0.16 0.25
Optimal Sel 0.3 0 0 0 0.6 0.6 9.2 29.4 59.9
A u01 = 0.6 Sel 0 0 0 0.3 3.3 22.6 27.9 25.6 20.3 0
Pts 0 3.1 3.1 3.3 3.5 4.1 1.1 1.5 1.3 1.1 21.0
u01 = 0.2 Sel 0 0 0 0.3 4.3 95.4 0 0 0 0
Pts 0 3.1 3.1 3.4 3.9 7.5 0 0 0 0.6 21.0
B u01 = 0.6 Sel 0 0 0 0.3 3.0 24.4 38.0 0.5 33.8 0
Pts 0 3.1 3.1 3.4 0.9 4.6 2.8 0.7 2.4 1.4 21.0
u01 = 0.2 Sel 0 0 0 0.3 4.3 30.2 20.7 11.0 33.5 0
Pts 0 3.1 3.1 3.3 1.1 4.3 3.0 0.7 2.4 1.4 21.0
C Sel 0 0 0 0.1 2.1 23.5 26.2 13.3 34.8 0
Pts 0 3.0 3.1 3.3 0.9 4.5 3.1 0.7 2.4 1.4 21.0
D Sel 0 0 0 0.3 46.2 53.5 0 0 0 0
Pts 0 3.0 3.0 3.7 9.4 1.9 0 0 0 0.6 21.0
E Sel 0 0 0 0.3 0.6 6.8 21.1 13.2 58.0 0
Pts 0.1 3.0 3.1 3.2 0.3 4.1 1.5 3.1 2.6 1.6 21.0
Sc.: Scenarios; pTox: true probability of toxicity in humans; Sel: proportion of times of declaring a dose as MTD; Pts: average number
of patients allocated to a dose.
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